Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4ONW5)

Drug Name
Baricitinib Drug Info
Synonyms Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [2]
Cross-matching ID
PubChem CID
44205240
ChEBI ID
CHEBI:95341
CAS Number
CAS 1187594-09-7
TTD Drug ID
DM4ONW5
VARIDT Drug ID
DR00322
INTEDE Drug ID
DR2502
ACDINA Drug ID
D00859

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Janus kinase 2 (JAK-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Momelotinib DMF98Q0 Myelofibrosis 2A20.2 Approved [9]
Ruxolitinib DM7Q98D Essential thrombocythemia 3B63.1Z Approved [10]
Pacritinib DM1T6ZN Myelofibrosis 2A20.2 Approved [11]
Fedratinib DM4ZBK6 Myelofibrosis 2A20.2 Approved [12]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [13]
XL019 DMJ6F5C Solid tumour/cancer 2A00-2F9Z Phase 3 [13]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [14]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [15]
INCB039110 DMD9RV3 Malignant neoplasm 2A00-2F9Z Phase 2 [16]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tyrosine-protein kinase (PTK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Abrocitinib DM8J29L Atopic dermatitis EA80 Approved [18]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [15]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [19]
KD019 DMEFW3G Brain metastases 2D50 Phase 2 [19]
LEO 124249 DM7W0JE Asthma CA23 Phase 2 [18]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [18]
TD-1473 DMJG7AY Ulcerative colitis DD71 Phase 1 [15]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [20]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [20]
PMID27774824-Compound-Figure11Example1up DMH1W8F N. A. N. A. Patented [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Janus kinase 1 (JAK-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ruxolitinib DM7Q98D Essential thrombocythemia 3B63.1Z Approved [10]
Upadacitinib DM32B5U Rheumatoid arthritis FA20 Approved [21]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [22]
SHR0302 DMUL8ZT Ulcerative colitis DD71 Phase 3 [23]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [18]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [15]
INCB039110 DMD9RV3 Malignant neoplasm 2A00-2F9Z Phase 2 [22]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [18]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [24]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [25]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [26]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [27]
Methotrexate DM2TEOL Anterior urethra cancer Approved [28]
Folic Acid DMEMBJC Colorectal carcinoma Approved [29]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [28]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [28]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [30]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [28]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [31]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Breast cancer resistance protein (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [33]
Methotrexate DM2TEOL Anterior urethra cancer Approved [34]
Folic Acid DMEMBJC Colorectal carcinoma Approved [35]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [36]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [37]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [38]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [39]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [38]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [40]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [42]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [43]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [44]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [45]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [46]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [47]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [48]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [49]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [43]
Verapamil DMA7PEW Angina pectoris BA40 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-G-associated kinase (GAK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [51]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [52]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [53]
Arsenic DMTL2Y1 N. A. N. A. Approved [54]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [55]
Tocopherol DMBIJZ6 N. A. N. A. Phase 2 [56]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [57]
4-hydroxy-2-nonenal DM2LJFZ Discovery agent N.A. Investigative [58]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [59]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By AP2-associated protein kinase 1 (AAK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [52]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [60]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [53]
Folic Acid DMEMBJC Colorectal carcinoma Approved [61]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [62]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [63]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [64]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [65]
Urethane DM7NSI0 N. A. N. A. Phase 4 [66]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [67]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Modulator [3]
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Modulator [3]
Tyrosine-protein kinase (PTK) TTJSQEF NOUNIPROTAC Inhibitor [1]
HUMAN adaptor-associated kinase 1 (AAK1) TTN9A16 AAK1_HUMAN Inhibitor [4]
HUMAN cyclin G-associated kinase (GAK) TT0AGBL GAK_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [5]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
AP2-associated protein kinase 1 (AAK1) OTK9B9QT AAK1_HUMAN Gene/Protein Processing [8]
Cyclin-G-associated kinase (GAK) OTLM5H4P GAK_HUMAN Gene/Protein Processing [8]

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 ClinicalTrials.gov (NCT04345289) Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. U.S. National Institutes of Health.
3 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
4 Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31.
5 Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17.
6 Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clin Transl Sci. 2017 Nov;10(6):509-519.
7 FDA label of Baricitinib. The 2020 official website of the U.S. Food and Drug Administration.
8 COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
9 Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
10 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
11 National Cancer Institute Drug Dictionary (drug id 609888).
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
13 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
14 Company report (Portola Pharmaceuticals)
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
17 Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
21 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
23 Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
24 Clinical pipeline report, company report or official report of Aclaris Therapeutics.
25 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
26 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
27 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
28 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
29 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
30 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
31 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
32 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
33 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
34 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
35 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
36 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
37 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
38 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
39 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
40 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
41 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
42 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
43 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
44 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
45 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
46 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
47 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
48 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
49 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
50 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
51 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
52 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
53 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
54 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
55 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
56 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
57 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
58 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
59 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
60 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
61 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
62 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
63 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
64 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
65 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
66 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
67 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.